Capecitabine Accord 500 mg film-coated tablets
Sponsors
Fondation Franc.Cancerologie Digestive, Astrazeneca AB, Bristol-Myers Squibb Services Unlimited Company, Exscientia AI Limited, Centre Hospitalier Universitaire De Dijon
Conditions
Advanced solid tumorsAmpullary adenocarcinomaBiliary tract cancerBiliary tract carcinomaLocally Advanced Unresectable Esophageal Squamous Cell CarcinomaMMRp/ MSS colon cancerMetastatic Breast CancerPan tumor
Phase 1
A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors
RecruitingCTIS2023-508227-13-00
Start: 2023-06-19Target: 112Updated: 2026-01-14
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
Active, not recruitingCTIS2023-505690-33-00
Start: 2022-03-11Target: 12Updated: 2026-01-21
NEOadjuvant chemotherapy only compared with standard treatment for Locally Advanced Rectal cancer: a randomized phase II trial
Active, not recruitingCTIS2024-517748-76-00
Start: 2016-11-14Target: 124Updated: 2024-10-08
Phase 2
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carcinoma. A non-comparative randomized phase II study
CompletedCTIS2023-503807-27-00
End: 2023-08-29Target: 219Updated: 2023-07-07
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Start: 2020-05-05Target: 307Updated: 2026-01-19
A multicenter open-label randomized controlled prospective phase II study evaluating the efficacy of Selective Internal Radiation Therapy (Yttrium-90 glass microspheres) combined with Capecitabine in the neoadjuvant setting of Operable intrahepatic CHOlangiocarcinoma
RecruitingCTIS2024-516683-29-00
Start: 2022-02-04Target: 62Updated: 2025-05-13
A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 or Stage III MMRp/ MSS colon cancer
RecruitingCTIS2024-513441-36-00
Start: 2024-11-27Target: 170Updated: 2025-12-18
Phase 3
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN).
Active, not recruitingCTIS2023-506413-22-00
Start: 2021-03-31Target: 48Updated: 2026-01-09
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma.
RecruitingCTIS2024-511070-68-01
Start: 2024-09-24Target: 294Updated: 2025-08-29
PembroLizumab Adjuvant in patients with early-stage Triple NEgaTive breast cancer with residual disease after neoadjuvant pembrolizumab plus chemotherapy – the multicenter, randomized phase III, pragmatic PLANET trial
Not yet recruitingCTIS2025-524229-41-00
Target: 1000Updated: 2026-04-01